Millions of people are treated with antithrombotic drugs and major hemorrhages are the most threatening consequence. When this study was performed the prevalence in the general population of people treated with vitamin K-antagonists (VKA) was approximately 1%, and major hemorrhagic events occurred in 2–3% of patients treated with VKA [1-3]. The mortality of intracranial hemorrhage (ICH) occurring on anticoagulant treatment is 30–55%, with a very high morbidity in surviving patients [1-3]. When bleeding occurs, treatment to reverse anticoagulation should be started as soon as possible.
